Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches-Reference-Cited by-同舟云学术

Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches

Published:2021-03-03 Issue:5 Volume:5 Page:1340-1343
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Lahuerta Juan José¹^ORCID,Paiva Bruno²^ORCID,Jiménez de Ubieto Ana³^ORCID,Sánchez-Pina José³^ORCID,Mateos María-Victoria⁴^ORCID,Bladé Joan⁵^ORCID,San-Miguel Jesús F.²^ORCID

Affiliation:

1. Instituto de Investigación Sanitaria Hospital 12 de Octubre, Fundación PETHEMA, CIBERONC number CB16/12/00369, Madrid, Spain;

2. Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBERONC number CB16/12/00369, Pamplona, Spain;

3. Hospital 12 de Octubre, Madrid, Spain;

4. Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBERONC number CB16/12/00233 Salamanca, Spain; and

5. Hospital Clínic IDIBAPS, Barcelona, Spain

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/5/5/1340/1802314/advancesadv2020003996.pdf

Reference29 articles.

1. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group;Laubach;Leukemia,2016

2. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial;San-Miguel;Lancet Oncol,2014

3. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study;Dimopoulos;Lancet Oncol,2016

4. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma;Stewart;N Engl J Med,2015